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OBJECTIVES The goal of this study was to determine if a low-dose combination of the angiotensin-
converting enzyme inhibitor perindopril (Per) and the diuretic indapamide (Ind) reduces
central (thoracic aorta, carotid artery) as well as brachial systolic blood pressure (SBP) more
than the beta-blocker atenolol and to determine the hemodynamic factors influencing
independently brachial and central SBP: pulse wave velocity (PWV) and pattern of wave
reflections.
BACKGROUND In high cardiovascular risk populations, angiotensin blockade improves survival without
affecting brachial SBP and diastolic blood pressure (DBP). Whether central SBP, which is
physiologically lower than brachial SBP, is significantly reduced has never been investigated.
METHODS This study was a double-blind randomized trial for one year in patients with essential
hypertension.
RESULTS For a similar DBP reduction, Per/Ind decreased SBP significantly more than atenolol, with
a more pronounced reduction for central than for brachial SBP. After one year, the difference
between brachial and central SBP was maintained by Per/Ind (8.28  1.53 mm Hg) and
significantly attenuated by atenolol (0.29  1.61 mm Hg). Under atenolol, the principal
factor modulating SBP reduction was mean blood pressure. Under Per/Ind, this parameter
played a minor role, and the central SBP reduction implied a major role for disturbed PWV
and wave reflections.
CONCLUSIONS Under Per/Ind, but not atenolol, normalization of brachial SBP is achieved with a
significantly greater reduction of central SBP. This hemodynamic profile reflects changes of
wave reflections issued from distal arterial and arteriolar territory, where Per/Ind, but not
atenolol, is known to improve vessel wall structure. (J Am Coll Cardiol 2004;43:92–9)
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In several high cardiovascular (CV) risk populations (1–4),
it has been suggested that angiotensin-converting enzyme
inhibitors (ACEI) or angiotensin II antagonists reduce CV
morbidity and mortality without a change in conventional
brachial cuff systolic blood pressure (SBP) and diastolic
blood pressure (DBP). This assumption may be questioned
on several grounds. First, most of the patients were previ-
ously treated for hypertension, and baseline brachial SBP
and DBP at inclusion were very close to normal. Under
these conditions, brachial blood pressure may be difficult to
modify by antihypertensive agents, particularly in subjects
where only baseline brachial SBP is slightly elevated. Sec-
ondly, central SBP is a very complex parameter. Whereas
mean blood pressure (MBP) and even DBP remain rela-
tively stable along the arterial tree, SBP is lower in central
(thoracic aorta, carotid artery) than in peripheral (brachial)
arteries, as a consequence of the summation of incident and
reflected pressure waves close to peripheral reflecting sites.
Thus, it is relevant to propose that blockade of the renin-
angiotensin system might reduce central SBP without major
change in brachial SBP, a hemodynamic pattern already
observed with other CV vasodilators as nitrates (5). Taken
together, these findings focus attention on the hemody-
namic mechanisms, such as large artery stiffness and wave
reflections, which influence selectively SBP and have the
potential to better reduce CV risk in hypertensive popula-
tions (6,7).
The association of the ACEI perindopril (Per) with the
diuretic compound indapamide (Ind) has been shown to
reduce significantly CV morbidity and mortality (8). When
compared with atenolol in hypertensive subjects, the Per/
Ind combination reduces more SBP than atenolol for the
same reduction of DBP. The finding was observed at
both the brachial and central (thoracic aorta, carotid artery)
levels (9). However, several problems had not yet been
clarified. First, it was not verified that normal brachial
SBP (140 mm Hg) under Per/Ind was associated with
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lower values of central SBP. Second, it was not determined
at which exact period the selective SBP reduction was
obtained during the one-year follow-up. Finally, the factors
modulating independently brachial and central SBP reduc-
tion under Per/Ind or atenolol have not been extensively
explored. This report presents new data enabling determi-
nation from month 0 (M0) to month 12 (M12) the
time-dependent relationships of the main hemodynamic
factors influencing the central SBP reduction: wave reflec-
tions, arterial stiffness, and/or the cardiac changes generated
by atenolol.
The aim of the present study was to determine the
hemodynamic mechanisms explaining the selective SBP
reduction obtained with the Per/Ind combination when
compared with atenolol, to establish in which conditions
such mechanisms varied with time along the one-year
follow-up of the study and, finally, to determine whether
they differ in the central and peripheral compartments of the
arterial tree.
METHODS
The REASON Project (pREterax in regression of Arterial
Stiffness in a contrOlled double-bliNd study) is a multi-
center, randomized, double-blind, two parallel group study
already conducted in 13 countries (9). After a one-month
washout placebo period, 471 hypertensive patients, age 18
to 83 years, were selected with a supine SBP 160 mm Hg
and 210 mm Hg, and/or a supine DBP 95 mm Hg and
110 mm Hg. Exclusion criteria as well as biochemical
changes have been published in detail elsewhere (9). Writ-
ten informed consent was obtained from each patient, and
the protocol was approved by the ethics committees, in
accordance with local regulations.
Patients were randomly allocated to receive either Per 2
mg/Ind 0.625 mg or atenolol 50 mg for a 12-month
follow-up period. In both groups, the medication was taken
orally in the morning as a single dose. For treatment
adaptation, the dose was doubled (two capsules once daily)
(n  103 for Per/Ind and n  92 for atenolol) after three
months if SBP remained 160 mm Hg and/or DBP 90
mm Hg.
Hemodynamic variables were determined 24 h after the
last drug intake, just before inclusion (M0), at month 6
(M6), and at the end of the follow-up (M12) using a
protocol described in detail elsewhere (9). Brachial SBP and
DBP were determined with mercury sphygmomanometer.
Pulse wave velocity (PWV) was measured in all subjects,
and pulse wave analysis was performed in 181 subjects
randomly selected. All measurements were analyzed by two
physicians blinded to treatment, clinical data, and physical
examination. The PWV was determined using an automatic
device, the Complior (Colson, Paris, France). Available data
(9) were obtained in 469 of the 471 patients. For pulse wave
analysis, measurements were performed in 181 subjects,
involving 144 subjects for the carotid artery and 110 for the
aorta. Determinations were performed by applanation
tonometry using a Sphygmocor device (Alcor, Sydney,
Australia) (10) and assuming identical values of MBP and
DBP in the totality of the arterial tree (9–12). Calibration
and repeatability have been described in detail elsewhere
(9,11,12). On the carotid and aortic blood pressure curve,
the carotid augmentation index (AIc) and aortic augmen-
tation index (AIa), which evaluate the delay of carotid or
aortic wave reflections and their effect on the height of SBP
and the left ventricular ejection time (LVET), were deter-
mined according to previously validated methods (9–12).
Cardiac index, stroke index, and total peripheral resistance
were determined at M0 and M12 using standard echocar-
diography (9). The stroke index on LVET ratio was used as
an index of ventricular ejection.
In this study, an intention-to-treat (ITT) analysis was
performed, using a SAS software version 8.2 (Cary, North
Carolina) for Windows. Means and SDs are given for the
description of quantitative variables, and percentage on total
categories sample size for qualitative variables. Because the
main goal was to investigate the time-dependency of simul-
taneous determinations of brachial and central parameters,
adjustments involved in all comparisons age, gender, body
mass index, prior antihypertensive drug therapy, and treat-
ment adaptation if necessary. Other pertinent variables such
as heart rate or MBP were potentially added. Treatment
group, time of measurements (visits), and interaction group
by time were initially tested by a repeated measures analysis.
Because of a positive interaction group by time, these two
main effects were analyzed separately: time effect test in each
group, and group effect at each time. Absolute means
analysis variations according to the therapeutic groups and
time were analyzed by a general linear model, and baseline
values were taken additionally as covariates for 6- and
12-month mean comparisons. Adjusted means were derived
from this model.
Central-peripheral SBP amplification was determined as
brachial SBP  carotid SBP and expressed in mm Hg.
Changes between visits were computed as: 6-month value
(M6)  baseline value (M0)  by baseline value  100;
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme
inhibitor
AIa  augmentation index (aortic)
AIc  augmentation index (carotid)
CV  cardiovascular
DBP  diastolic blood pressure
Ind  indapamide
ITT  intention-to-treat
LVET  left ventricular ejection time
MBP  mean blood pressure
M0, M6, M12  month 0, month 6, month 12
Per  perindopril
PP  pulse pressure
PWV  pulse wave velocity
SBP  systolic blood pressure
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12-month value  6-month value  6-month value  100;
12-month value (M12)  baseline value (M0)  baseline
value  100. Stroke change (%) between therapeutic groups
at each time were analyzed by a general linear model, and
adjusted means were derived from this model. Regression
coefficients were obtained by linear regression procedures.
Stepwise linear regressions were used to establish the order
of trend between the percent change of SBP and the
different percent change in the hemodynamic variables
influencing SBP: AIc or AIa (%), LVET in ms, PWV in
m/s, MBP in mm Hg. Age in years, body mass index in
kg/m2, and three dummy variables (previous antihyperten-
sive treatment, therapeutic adaptation, gender) were again
used as covariates.
RESULTS
Population descriptions. The per protocol and ITT anal-
ysis of the REASON project have been presented in detail
elsewhere (9). Table 1 presents the global ITT population
(n  469) and the population of the ancillary study (n 
181), in which pulse wave analysis was performed.
For the global ITT population (n  469), the baseline
values of blood pressure and the clinical characteristics did
not differ between the two drug regimens: Per/Ind and
atenolol (Table 1). Figure 1 shows that, whereas brachial
DBP decreased with time significantly (p  0.001) and
similarly in both treatment groups, brachial SBP decreased
more with Per/Ind than with atenolol (9). The difference
between the two groups became significant (p 0.011) only
at the end of the follow-up (M12).
For the population with pulse wave analysis (n  181),
the baseline characteristics did not differ from those of the
global ITT population, whatever the drug regimen may be
(Table 1). Because we verified that, under drug treatment,
the SBP changes and those of the other hemodynamic
variables did not differ between the two populations,
whether without (n  469) or with (n  181) pulse wave
analysis, only the changes of the latter population are now
presented in this report.
Study of mean values under drug treatment. Table 2
compares at M0, M6, and M12 the mean values of
blood pressure measurements and other hemodynamic vari-
ables under Per/Ind and under atenolol. Whereas no sig-
nificant difference was observed at M0 between Per/Ind and
atenolol, significant differences were observed at M12 re-
garding brachial, carotid, and aortic SBP as well as SBP
amplification.
Regarding brachial, carotid, and aortic SBP, the mean
values ( SE) at M12 were significantly lower under
Per/Ind than under atenolol. In addition, the SBP amplifi-
cation, that is, the difference between brachial and carotid
SBP (adjusted means  SE) at M0 was 9.40  1.54 for
Per/Ind and 9.64  1.50 mm Hg for atenolol (p  NS).
At M12, this difference was, respectively, 8.28  1.53 and
0.29  1.61 (p  0.0006), indicating that, under Per/Ind,
SBP amplification was maintained, whereas it was reduced
under atenolol.
Brachial, carotid, and aortic DBP and MBP did not differ
between the two drug regimens, whether at M0, M6, or
M12. Heart rate was significantly reduced (p  0.0001),
and LVET increased under atenolol and not under Per/Ind.
At M12, AIc (p  0.0527) and AIa (p  0.0057) differed
between the two drug regimens. These differences disap-
peared after adjustment for heart rate or LVET variation.
At M0, M6, and M12, PWV did not differ between the
two drug regimens. The same findings were observed for
MBP, cardiac and stroke index, total peripheral resistance,
and mainly the stroke index on LVET ratio (data not
shown).
Factors influencing the brachial and central SBP reduc-
tion (%) during the follow-up. In the population with
pulse wave analysis (n  181), the percent reduction of
Table 1. Population Descriptions: Main Parameters at Baseline (Mean  SD) in the Global ITT Population (n  469, Because in
2 Subjects, PWV Measurements Were Not Available at Baseline) and in the Population of the Ancillary Study With Central
Measurements (n  181)
ITT Population (n  469)
Subpopulation With Central
Measurements (n  181)
Per/Ind
(n  235)
Atenolol
(n  234)
Per/Ind
(n  88)
Atenolol
(n  93)
Gender (men:women) (%) 66:34 69:31 69:31 76:34
PAT (yes) (%) 73 72 70 74
Trt Adapt (Yes) (%) 44 39 51 42
Age (yrs) 55.0  12.2 54.8  12 55.9  13.4 57.5  14.4
Body mass index (kg/m2) 26.9  2.9 26.6  2.8 27.0  3.2 26.6  3.0
SBP (mm Hg) 163.1  13.4 161.4  14.8 165.3  13.9 162.5  15.0
DBP (mm Hg) 98.6  6.8 98.6  7.0 97.4  8.2 96.1  8.1
MBP (mm Hg) 120.1  6.4 119.5  7.0 120.0  7.0 118.2  6.9
PP (mm Hg) 64.5  14.9 62.9  16.0 68.0  16.5 66.4  17.9
Heart rate (beats/min) 72.2  9.7 72.4  9.5 70.4  10.4 70.3  8.5
PWV (m/s) 12.20  2.91 12.32  2.87 12.78  3.02 12.59  3.02
DBP  diastolic blood pressure; Ind  indapamide; ITT  intention-to-treat; MBP  mean blood pressure; PAT  previous antihypertensive treatment; Per  perindopril;
PP  pulse pressure; PWV  pulse wave velocity; SBP  systolic blood pressure; Trt Adapt  treatment adaptation during the study.
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blood pressure and other hemodynamic variables is studied
from M0 to M6, M6 to M12, and, finally, M0 to M12.
Table 3 indicates the degree of significance of the time and
group effects of the different variables. After six months of
treatment, carotid SBP tended to continue to decrease with
Per/Ind (p  0.06), but this decrease was significantly
attenuated (p  0.01) with atenolol. These findings largely
agree with those observed in Table 2.
Figure 2 indicates the mean values of the percent changes
of SBP under each of the two drug regimens. Both with
brachial and carotid measurements, the SBP reduction was
significantly more pronounced with Per/Ind than with
atenolol. The difference between the two drug regimens was
even more significant for central than for brachial measure-
ments.
Table 4 indicates the hemodynamic factors influencing
the brachial and carotid (or aortic) SBP (%) reduction
during the different periods of the study: M0 to M6, M6 to
M12, and M0 to M12. The table indicates, first, the
contribution of MBP (in terms of partial variance) and,
second, the possible contribution of the other hemodynamic
and clinical variables (for this, see the statistical analysis).
When the brachial blood pressure measurements alone are
considered (Table 4, upper), whether with Per/Ind or
atenolol, MBP change (%) was the principal (and even the
unique) factor influencing the SBP change (%). The MBP
represented 65% to 86% of partial variance. When the
carotid measurements were considered (Table 4, lower), the
MBP changes (%) did not contribute or slightly contributed
to total variance: 14% for atenolol from M0 to M12, and
12% for Per/Ind from M6 to M12. With Per/Ind, the PWV
changes (%) played a significant role in the carotid SBP (%)
reduction from M0 to M6 and M0 to M12, whereas AIc
played an additional role only between M0 and M6.
Finally, for the mechanism(s) of SBP reduction (%) under
atenolol, the systemic MBP reduction had a major role for
Figure 1. Overall intention-to-treat population: adjusted values ( SD) in brachial systolic blood pressure (SBP) and diastolic blood pressure (DBP),
measured each month (M) in perindopril/indapamide (Per/Ind) and atenolol groups. There was no difference between groups for DBP but only for SBP
and exclusively at M12.
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both brachial and central measurements. Under Per/Ind,
MBP did not influence markedly the carotid SBP reduction
(%). Only PWV played a significant role from M0 to M12,
whereas AIc (or AIa) played a role only between M0 and
M6.
DISCUSSION
In the REASON study, we identified in the past (9) that,
whereas the decrease in brachial and central DBP was
similar in both treatment groups, the Per/Ind combination
had a more marked effect than atenolol on brachial SBP and
mostly on central SBP. In the present report, we observed
three additional new results. First, under Per/Ind at M12,
even when brachial SBP was below 140 mm Hg, central
SBP was substantially lower, whereas with atenolol this
physiological amplification was attenuated or even had
disappeared. Second, the higher reduction of SBP under
Per/Ind than under atenolol became significant only at the
end of the one-year follow-up. Third, the mechanism(s) of
SBP reduction differed substantially between atenolol and
Per/Ind, implying in the latter the active role of muscular
large arteries with resulting changes in arterial stiffness and
wave reflections and, in the former, the passive conse-
quences of MBP reduction (9–13).
It is well established that any blood pressure curve
involves two different components: a steady component,
MBP, influenced by cardiac output and vascular resistance,
and a pulsatile component, pulse pressure (PP). Using this
approach, whereas systemic MBP keeps closely the same
level along the totality of the arterial tree, PP (and mostly
SBP) is known to be significantly lower in central (carotid)
than in peripheral (brachial) arteries, in relation to the
well-established mechanism of wave reflections (10). In the
present study, we showed that this difference between
central and peripheral SBP was maintained under Per/Ind
but not under atenolol. In addition, we showed that the
specific contribution of MBP to the SBP reduction (%) was
of major importance only when brachial, but not carotid or
aortic, measurements were considered. Thus, when central
measurements are analyzed, it is possible to evaluate, inde-
pendently of MBP, the role of the specific factors influenc-
ing central SBP under Per/Ind or atenolol: pattern of
Table 2. Population With Central Measurements (n  181): Main Cardiovascular Parameters: Adjusted Absolute Means  Standard
Error of Means Are Presented at M0, M6, M12
Time Per/Ind Atenolol p*
Brachial SBP (mm Hg) M0 165.65  1.40 162.18  1.36 0.0786
M6 142.39  1.39 147.32  1.39 0.0144
M12 137.80  1.34 142.88  1.41 0.0119
Carotid SBP (mm Hg) M0 154.46  1.95 152.37  1.90 0.4431
M6 133.34  1.62 141.23  1.64 0.0010
M12 129.50  2.16 144.99  2.20 <0.0001
Brachial-carotid SBP (mm Hg) amplification M0 9.40  1.54 9.64  1.50 0.9125
M6 6.37  1.50 2.43  1.54 0.0709
M12 8.28  1.53 0.29  1.61 0.0006
Aortic SBP (mm Hg) M0 155.63  1.83 151.23  1.80 0.0891
M6 135.22  1.78 143.40  1.84 0.0020
M12 128.32  1.97 140.58  2.07 <0.0001
Brachial DBP (mm Hg) (or carotid or aortic) M0 97.09  0.77 96.33  0.75 0.4822
M6 85.10  0.79 85.21  0.79 0.9202
M12 83.93  0.74 83.36  0.78 0.6005
Brachial MBP (mm Hg) (or carotid or aortic) M0 119.94  0.75 118.28  0.73 0.1137
M6 104.19  0.87 105.92  0.87 0.1659
M12 101.83  0.83 103.26  0.87 0.2463
Heart rate (beats/min) M0 70.12  1.00 70.56  0.97 0.7564
M6 69.79  0.79 63.01  0.79 <0.0001
M12 70.10  0.90 62.74  0.95 <0.0001
Carotid LVET (ms) M0 333.65  2.67 335.88  2.65 0.5555
M6 332.05  2.49 349.25  2.60 <0.0001
M12 329.29  2.52 341.76  2.76 0.0014
Carotid augmentation index (%) (AIc) M0 29.09  2.24 28.77  2.16 0.9175
M6 25.97  2.13 27.74  2.14 0.5608
M12 24.39  1.88 29.73  1.93 0.0527
Aortic augmentation index (%) (AIa) M0 30.06  0.98 30.30  0.97 0.8616
M6 27.50  0.91 30.97  0.95 0.0101
M12 26.28  0.94 30.18  1.00 0.0057
PWV (m/s) M0 12.91  0.26 12.46  0.25 0.2161
M6 11.90  0.21 12.02  0.21 0.7008
M12 11.77  0.23 11.90  0.24 0.6945
*p intergroup significant comparisons are presented in bold characters.
LVET  left ventricular ejection time; M0, M6, M12  Month 0, Month 6, Month 12; other abbreviations as in Table 1.
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ventricular ejection, change of aortic PWV and/or AIc (or
AIa), and, finally, modifications in vascular reflectance
(change in the site and/or intensity of wave reflections) (10).
Because, during the follow-up, we showed that changes
in ventricular ejection and PWV did not differ between the
two drug regimens, none of these factors alone could explain
the selective SBP reduction under Per/Ind. Only heart rate
and LVET should have to be taken into consideration for a
possible contribution of cardiac factors to the central SBP
reduction (%). The reduction of heart rate and the longer
LVET produced by the beta-blocking agent atenolol may
have delayed the peak of the forward wave, which induces
an increase of AIc (or the AIa) and, therefore, modified
more the AIc (or AIa) changes with atenolol than with
Per/Ind (10). However, we and others (9,14,15) have
previously shown that the differential role of this factor
disappears after adjustment to LVET or heart rate and,
thus, played a minor role in this study. Finally, the weight of
evidence suggests that the central SBP reduction (%) cannot
be influenced by a single hemodynamic parameter but rather
by the modulation of the overall hemodynamic alterations,
which varied substantially with time during the follow-up
for each drug regimen (9,14,15). In this context, we showed
that, under Per/Ind, PWV influenced SBP reduction from
M0 to M12, whereas AIc (or AIa) influenced SBP reduc-
tion only from M0 to M6 (Table 4). In addition, the
significant difference in SBP reduction between Per/Ind and
atenolol was mostly observed at M12 (Fig. 1). Thus, the
overall results suggest that, at the end of the follow-up, the
Per/Ind-induced changes of arterial stiffness were associated
with structural, rather than functional, alterations of the
vessel walls, thereby altering the transit time from the
peripheral reflection sites toward central arteries and chang-
ing the timing of incident and reflected waves.
In untreated hypertensive subjects, it is well established
that the wall on lumen ratio of musculo-elastic proximal
arteries, of muscular distal arteries, and of arterioles is
significantly increased (16,17). After one year of treatment
by ACEI with or without diuretics (16,17), the wall/lumen
ratio of muscular distal arteries and of arterioles (but not of
proximal musculo-elastic arteries) is significantly reduced
(17,18), in conjunction with changes in endothelial function
and smooth muscle tone (16,17). In parallel, and under the
same durations of treatment, it has been shown that the
pattern of wave reflections is significantly modified by
ACEI, involving a reduction in reflection coefficients of
distal muscular arteries and arterioles and a decrease in the
amplitude of the backward pressure wave (14,19). All these
Table 3. Population With Central Measurements (n  181): Main Cardiovascular Parameters: Adjusted % Means  Standard Error
of Means Are Presented at M0, M6, M12
Time Per/Ind Atenolol p*
Brachial SBP (mm Hg) M0–M6 13.27  0.85†§ 9.78  0.85†§ 0.0044
M6–M12 0.70  0.90 1.23  0.94 0.1433
M0–M12 15.05  0.85†§ 10.95  0.90†§ 0.0013
Carotid SBP (mm Hg) M0–M6 12.15  1.13†§ 6.53  1.14†§ 0.0007
M6–M12 2.60  1.36 4.56  1.46‡ 0.0006
M0–M12 14.46  1.52†§ 4.31  1.55‡ <0.0001
Aortic SBP (mm Hg) M0–M6 12.01  1.18†§ 6.04  1.22†§ 0.0007
M6–M12 2.20  1.20 1.67  1.30 0.0323
M0–M12 15.29  1.34†§ 6.50  1.40†§ <0.0001
Brachial DBP (mm Hg) (or carotid or aortic) M0–M6 11.81  0.85†§ 11.53  0.85†§ 0.8171
M6–M12 0.60  0.99 0.11  1.04 0.7371
M0–M12 12.89  0.81†§ 13.17  0.85†§ 0.8170
Brachial MBP (mm Hg) (or carotid or aortic) M0–M6 12.56  0.74†§ 10.81  0.74†§ 0.0972
M6–M12 0.05  0.84 0.53  0.89 0.6426
M0–M12 13.97  0.70†§ 12.29  0.74†§ 0.1059
Heart rate (beat/min) M0–M6 0.49  1.35 10.15  1.35†§ <0.0001
M6–M12 0.69  1.54 0.26  1.62 0.8506
M0–M12 0.34  1.41 10.89  1.48†§ <0.0001
Carotid LVET (ms) M0–M6 0.48  0.84 4.40  0.87†§ 0.0001
M6–M12 0.65  0.81 0.83  0.92 0.8834
M0–M12 1.22  0.85 2.61  0.93‡ 0.0035
Carotid augmentation index (%) (AIc) M0–M6 1.32  2.13 0.45  2.14 0.5608
M6–M12 2.78  1.91§ 2.18  2.03 0.0441
M0–M12 4.11  1.88§ 1.23  1.93 0.0527
Aortic augmentation index (%) (AIa) M0–M6 2.13  0.91§ 1.34  0.95 0.0101
M6–M12 1.33  0.92 1.41  1.02 0.0512
M0–M12 3.66  0.94† 0.25  1.00 0.0057
PWV (m/s) M0–M6 6.05  1.00† 4.05  1.64§ 0.3924
M6–M12 1.02  1.59 0.21  1.65 0.7261
M0–M12 6.47  1.94‡ 4.35  2.02§ 0.4572
*p intergroup significant comparisons are presented in bold characters; †p (time effect) 0.001; ‡p (time effect) 0.01; §p (time effect) 0.05; p  0.06.
Abbreviations as per Tables 1 and 2.
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changes are observed under ACEI (with or without diuret-
ics) but not under atenolol (14,17,19). Thus, it seems
relevant to propose that, under Per/Ind, the peripheral
modifications of vascular structure and function have mod-
ified the reflectance of peripheral arterial and arteriolar
vascular beds, thereby altering reflection coefficients and the
amplitude of wave reflections and contributing to reduce
central SBP. In this context, it is noteworthy that changes in
sodium balance (8,9,14,17) and in the renin-angiotensin
system (14,16,17) may substantially influence the geometry,
the physical properties, the tone, and the effective number of
smaller arteries and arterioles, particularly at their branching
points (10).
As mentioned in the introduction, the results of several
therapeutic trials in high CV risk populations (1–4) have
suggested that ACEI or angiotensin II antagonists might
reduce CV risk “beyond blood pressure control.” However,
other therapeutic trials, also performed in populations with
high CV risk (20) have suggested that the pharmacologic
treatment of hypertension improves more substantially CV
mortality when two different hemodynamic alterations are
independently achieved: 1) the MBP reduction should be
associated with a PWV attenuation and a selective reduction
of SBP and pulse pressure; and 2) an ACEI should be given
among the various antihypertensive agents displayed during
the follow-up. All these results taken together suggest that
ACEI cannot be considered as acting on CV risk without a
substantial effect on SBP and DBP. In order to demonstrate
the point, the principal condition is that central blood
pressure measurements, and not only brachial blood pres-
sure measurements, should be measured. This proposition
agrees with the recent evidence that prediction of CV risk is
Figure 2. Population with central measurements: adjusted changes ( SD)
in systolic blood pressure (SBP) (%). With perindopril/indapamide (Per/
Ind) (lined bars), SBP reduction (%) was more pronounced than for
atenolol (open bars) at both the carotid and the brachial artery sites
between 0 to 6 months and 0 to 12 months. Between 6 to 12 months, the
SBP reduction continued under Per/Ind and tended to decline under
atenolol. The p values are represented as Per/Ind versus atenolol.
Table 4. Factors Modulating Brachial and Carotid Adjusted-SBP Changes (%) Under Drug Treatment: Stepwise Linear Regressions
for Brachial (Upper Panel) and Central (Lower Panel) Measurements
Brachial Artery SBP Measurements
Period MBP 1° Var CR (SE) R2 p
Per/Ind M0–M6 78% PWV 0.07 (0.03) 2% 0.0204
Atenolol 73% — — — —
Per/Ind M6–M12 77% — — — —
Atenolol 80% — — — —
Per/Ind M0–M12 86% — — — —
Atenolol 65% — — — —
Carotid Artery SBP Measurements
Period MBP 1° Var CR (SE) R2 p 2° Var CR (SE) R2 p
Per/Ind M0–M6 No PWV 0.24 (0.08) 14% 0.003 AIc 0.14 (0.05) 8% 0.0158
Atenolol No Trt Adapt 6.42 (2.389) 13% 0.008 PAT 6.56 (2.69) 9% 0.0182
Per/Ind M6–M12 12%
Atenolol No
Per/Ind M0–M12 No PWV 0.21 (0.08) 11% 0.014
Atenolol 14%
Only the significant variables of the regression are presented in the table. (Y axis  SBP [brachial or carotid] change; X axis  [LVET, AIc, PWV and MBP changes]).
AIc  augmentation index (carotid); CR (SE)  regression coefficient and standard error; MBP (%)  partial variance of mean blood pressure explained if a significant link
with SBP (p  0.05) is observed; No  no significant link with SBP; P  significance of link with SBP; R2  % partial variance explained; 1° Var  first variable in the final
equation; 2° Var  second variable in the final equation; other abbreviations as in Tables 1 and 2.
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more adequately evaluated from central rather than from
brachial blood pressure measurements (21).
In conclusion, the present investigation has shown that,
in subjects with essential hypertension, the Per/Ind combi-
nation reduces SBP more than the standard comparator
atenolol for the same decrease of DBP. This highly signif-
icant differential effect, which is not obtained with ACEI
alone (14), is more pronounced in central than in peripheral
arteries. The decrease in central SBP reflects a significant
improvement of large artery function and a changing pattern
in both peripheral reflection coefficients and structural
arteriolar network, two modifications commonly observed
under ACEI treatment within the distal compartment of
the hypertensive arterial tree. Finally, the selective SBP
reduction under Per/Ind requires the simultaneous alter-
ations of both macrocirculation and microcirculation.
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